# Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

> **NCT06726785** · — · RECRUITING · sponsor: **HBC Immunology Inc** · enrollment: 50 (estimated)

## Conditions studied

- Restless Leg Syndrome (RLS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06726785
- **Lead sponsor:** HBC Immunology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-02-27
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726785, "Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06726785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*